The U.S. Office of Research Integrity (ORI) announced today that a former graduate student committed research misconduct — nearly two years after his institution stripped him of his degree.
The ORI concluded that Shiladitya Sen committed misconduct in a PNAS paper (retracted six months ago), his PhD thesis, a poster presentation, and two grant applications to the National Institutes of Health (NIH). Sen has agreed not to seek federal funding for three years.
A spokesperson for The Ohio State University (OSU), where Sen was based, told us its investigation wrapped up in Spring 2016, and Sen’s PhD was revoked that June. It’s not clear why it took two years for the ORI to issue its own finding; the ORI did not immediately respond to requests for comment.
What Caught Our Attention: A tree of life paper has been axed — and based on the information in the retraction notice, we’re wondering how it ever passed peer review.
Specifically, the notice states a review of the paper found “concerns regarding the study design, methodology, and interpretation of the data.” Overall, the research “contradict(s) a large body of existing literature and do(es) not provide a sufficient level of evidence to support the claims made in the paper.” Um, so what did it get right?
A researcher has retracted two 2014 papers, after discovering they had not gone through the proper approval process before being submitted.
The papers were part of a collaboration funded by the U.S. National Institutes of Health, which focused on solving protein structures. Adam Godzik, the senior author, told Retraction Watch that all papers had to be approved by a special committee before being submitted to a journal. Given the scale of the collaboration, the committee for the Joint Center for Structural Genomics (JCSG) would assess whether researchers who had made a previous contribution to the work should be added as authors.
When the Proceedings of the National Academy of Sciencesretracted a gene therapy paper in December, it declared that some of the data had been falsified and mentioned a research misconduct investigation. But the notice said nothing about who was responsible.
Via a public records request, Retraction Watch has obtained investigation documents from the University of Florida, which show the focus had been narrowed down to two of the paper’s three co-first authors. But the investigation committee didn’t assign blame to either one. According to their final report, dated Oct. 24, 2016:
there was not enough direct evidence to either implicate or exonerate either of these individuals.
A pharmacy journal has retracted a 2017 cancer paper after determining that the lead author forged her co-author’s signature.
Alain Li Wan Po, editor-in-chief of the Journal of Clinical Pharmacy and Therapeutics, told Retraction Watch that, after discovering the forgery,the journal lost confidence in “the integrity of the whole report,” and decided to retract it:
Our judgment was that if an author is willing to forge a signature, we cannot be sure of the integrity of the whole report and decided on the retraction.
According to Po, the paper’s lead author, Yan Wang, objected to the retraction because “she maintained that the data were accurate.” So the editors retracted the paper without her approval — but with the agreement of the author Jatinder Lamba, whose name was forged.
How did the journal discover the forged signature?